Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Subscribe To Our Newsletter & Stay Updated
